At Alveus Therapeutics, we are building a differentiated therapeutic portfolio that delivers sustainable weight loss with superior tolerability, potentially improving patient outcomes, and addressing the critical challenge of weight maintenance that limits current treatments.
Explore our ScienceOur approach combines human genetic data, deep biological and clinical expertise, and rigorous program selection. We focus on targets with well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules that deliver transformative benefits in the evolving obesity treatment landscape.
More about scienceOur experienced leadership team brings proven success in metabolic disease drug development and pipeline building, backed by a Board with expertise across key functional areas.
Get to know our teamAlveus’s pipeline is focused on next-generation metabolic therapies; the lead asset ALV-100 is currently in Phase 2. The company’s preclinical amylin pipeline consists of best-in-class peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.
View our pipeline
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24-02-2026Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
23-01-2026Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
08-01-2026